research Editorial comment
Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
Search
for
Sort by
Research
630-660 / 1000+ resultsresearch Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
research Neurosteroid allopregnanolone attenuates development of nicotine withdrawal behavior in mice
Allopregnanolone may help prevent nicotine withdrawal symptoms.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N. Bennani and I. M. Bennani-Baiti
Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.
research Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders
New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
research Androgenetic alopecia
research Progestogens with Antiandrogenic Properties
research A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
research Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
Dutasteride effectively and safely treats male hair loss for over a year.
research Market Analysis of 5α-Reductase Inhibitor
The market for these drugs is expected to grow.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research Relapsing nail fibrokeratoma: A case report on a teenager
Dutasteride is more effective than finasteride for hair growth with similar side effects.
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Efficacy and Safety of Topical Flutamide 1% Gel as an Adjunctive Therapy in the Treatment of Patients With Acne Vulgaris
Topical Flutamide 1% gel effectively and safely reduces acne.
research SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study
The SULT1A1 enzyme booster improves minoxidil effectiveness in treating hair loss, especially in females.
research Similar Risk of Sexual Dysfunction in Androgenetic Alopecia Patients Treated With Dutasteride vs. Finasteride: A Retrospective Cohort Database Study
research AN EFFICIENT SYNTHESIS OF DUTASTERIDE: UTILIZING BENZOYL GROUP AS NOVEL LACTAMIC PROTECTING GROUP
Researchers created a new, efficient way to make Dutasteride, a hair loss and prostate drug, with high purity using a benzoyl group.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Enzyme-linked immunosorbent assays for doping control of 5α-reductase inhibitors finasteride and dutasteride
New tests detect finasteride and dutasteride in urine quickly and easily.
research Muscle pain in a woman with congenital adrenal hyperplasia due to 21-hydroxylase deficiency resolved with testosterone therapy. A case report with 10 years of follow-up
Testosterone therapy improved symptoms in a woman with congenital adrenal hyperplasia.
research Maculopapular Drug Eruption Caused by Finasteride: A Case Report
A man's rash caused by Finasteride improved after stopping the drug and starting new treatments.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research The Benefits of Dual Inhibition of 5α Reductase
Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial
Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
research Forum
The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.